Asset
PRALUZATAMAB RAVTANSINE
CytomX Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03149549 | phase1_2 | terminated | 2017-06-01 | 2020-09-10 | CytomX Therapeutics | PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors |
| NCT04596150 | phase2 | completed | 2020-12-29 | 2023-06-02 | CytomX Therapeutics | Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.